8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Feb 24, 2026·SEC
Edesa Biotech, Inc.(EDSA)Earnings, Financials & Key Ratios
EDSA•NASDAQ
$7.30
Price updated Jul 7, 2026
AboutEdesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.Show more
- Revenue$0
- EBITDA-$8M-14.1%
- Net Income-$7M-16.5%
- EPS (Diluted)-1.27+34.2%
- ROE-99.57%+27.1%
EDSA Price & Volume
Edesa Biotech, Inc. (EDSA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Reserves
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
Key Thesis Takeaways
- Edesa Biotech remains a high-risk, pre-revenue clinical-stage firm heavily dependent on external financing to sustain its monoclonal antibody development programs.
- While the company maintains a $10.0 million cash position as of 2026Q2, the persistent quarterly operating losses of $4.3 million suggest a narrowing runway that may necessitate further equity dilution.
- Investors should monitor the company's ability to achieve regulatory milestones, as the current $72.5 million accumulated deficit underscores the significant capital destruction inherent in its long-term research strategy.
Verdict Logic
the company's reliance on external funding to cover a $2.1 million quarterly free cash flow burn, combined with a $72.5 million accumulated deficit, presents an imminent risk of shareholder dilution.
EDSA Growth Metrics
Edesa Biotech, Inc. (EDSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-78.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.63%
Return on Capital
10 Years-102.94%
5 Years-150.22%
3 Years-125.47%
Last Year-109.63%
EDSA Recent Earnings
Edesa Biotech, Inc. (EDSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.49-104.2%
$0.24
Rev
$50,918+0.0%
$50,918
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.28+0.0%
$0.28
Rev
—
—
Q4 2025
Dec 12, 2025Metric
Actual
Est
EPS
$0.32-18.5%
$0.27
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.25+3.8%
$0.26
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.49vs $0.24-104.2% | $50,918vs $50,918+0.0% |
| Q1 2026 | Feb 13, 2026 | $0.28vs $0.28+0.0% | — |
| Q4 2025 | Dec 12, 2025 | $0.32vs $0.27-18.5% | — |
| Q3 2025 | Aug 8, 2025 | $0.25vs $0.26+3.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Edesa Biotech, Inc. (EDSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.30 | $64.91M | -5.75 | — | — | -99.57% | — | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $5.67 | $1.97B | -9.45 | 698.96% | -102.06% | -44.1% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Compare EDSA vs Peers
Edesa Biotech, Inc. (EDSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EDSA SEC Filings & Documents
Edesa Biotech, Inc. (EDSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when EDSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EDSA Frequently Asked Questions
Edesa Biotech, Inc. (EDSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is EDSA profitable?
Edesa Biotech, Inc. (EDSA) reported a net loss of $10.4M for fiscal year 2025.
Dividend & Returns
What is EDSA's return on equity?
Edesa Biotech, Inc. (EDSA) has a return on equity (ROE) of -99.6%. Negative ROE indicates the company is unprofitable.
What is Edesa Biotech, Inc.'s free cash flow?
Edesa Biotech, Inc. (EDSA) had negative free cash flow of $7.7M in fiscal year 2025, likely due to heavy capital investments.